Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study | |
Wu, Y. -L.2; Zhou, Q.3; Chen, M.4; Pan, Y.2; Jian, O.5; Hu, D.1; Lin, Q.6; Wu, G.7; Cui, J.8; Chang, J.9 | |
刊名 | JOURNAL OF THORACIC ONCOLOGY |
2022-09-01 | |
卷号 | 17 |
关键词 | CCRT sCRT PD-L1 inhibitor |
ISSN号 | 1556-0864 |
WOS研究方向 | Oncology ; Respiratory System |
语种 | 英语 |
出版者 | ELSEVIER SCIENCE INC |
WOS记录号 | WOS:000858678100012 |
内容类型 | 期刊论文 |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129843] |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Hubei Canc Hosp, Wuhan, Peoples R China 2.Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China 3.Guangdong Lung Canc Inst, Guangzhou, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 5.Second Peoples Hosp Neijiang, Neijiang, Peoples R China 6.Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China 7.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China 8.Jilin Univ, Hosp 1, Jilin, Peoples R China 9.Fudan Univ, Canc Ctr, Shanghai, Peoples R China 10.Shandong Univ, Qilu Hosp, Jinan, Peoples R China |
推荐引用方式 GB/T 7714 | Wu, Y. -L.,Zhou, Q.,Chen, M.,et al. Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study[J]. JOURNAL OF THORACIC ONCOLOGY,2022,17. |
APA | Wu, Y. -L..,Zhou, Q..,Chen, M..,Pan, Y..,Jian, O..,...&Yang, J..(2022).Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study.JOURNAL OF THORACIC ONCOLOGY,17. |
MLA | Wu, Y. -L.,et al."Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study".JOURNAL OF THORACIC ONCOLOGY 17(2022). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论